Adapting treatment length to opioid-dependent individuals' needs and preferences: A 2-year follow-up to a 1-year study of extended-release naltrexone.
Extended-release naltrexone
antagonist treatment
long-term treatment
opioid use
recovery
treatment duration
treatment of opioid dependence
Journal
Addiction (Abingdon, England)
ISSN: 1360-0443
Titre abrégé: Addiction
Pays: England
ID NLM: 9304118
Informations de publication
Date de publication:
18 Dec 2020
18 Dec 2020
Historique:
received:
29
05
2020
revised:
10
08
2020
accepted:
09
12
2020
entrez:
18
12
2020
pubmed:
19
12
2020
medline:
19
12
2020
Statut:
aheadofprint
Résumé
Extended-release naltrexone (XR-NTX) is an underused treatment option for opioid dependence, today only available in a few countries in the world. Although effective, safe and feasible in short-term treatment, long-term data are scarce and there is no recommendation for required treatment length. The aims of the study were to determine the perceived need of long-term XR-NTX treatment and to examine long-term treatment outcomes. In this prospective cohort study, following a parent 1-year study of XR-NTX, participants received treatment with XR-NTX at their own discretion for a maximum of 104 weeks. Five urban, outpatient addiction clinics in Norway. Opioid-dependent adults 18-60 years old (n=50) already participating in the parent study. XR-NTX administrated as intra-muscular injections (380 mg) every 4 weeks. Time in the study, use of opioids and other illicit substances, opioid craving, and treatment satisfaction reported every 4 weeks. Among 58 participants who completed the 1-year parent study, 50 chose to continue the treatment with XR-NTX. Median prolonged treatment time was 44.0 weeks (95% CI: 25.5-62.5), ranging from 8 to 104 weeks. Most participants (35, 70%) reported no relapse to opioid use during treatment while a subgroup (15, 30%) reported relapses to opioids during the study. Scores for mean treatment satisfaction and recommending treatment to others were very high (>9) and mean opioid craving score was very low (<1) on a scale ranging from 0 to 10. Extended-release naltrexone (XR-NTX) was well tolerated in long-term treatment of opioid dependent individuals in Norway already in XR-NTX treatment. On average, the participants chose to continue treatment for almost 1 year beyond the initial 9 to 12 months of treatment. Participants reported high treatment satisfaction and 70% showed no relapse to opioids during the treatment period.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
Extended-release naltrexone (XR-NTX) is an underused treatment option for opioid dependence, today only available in a few countries in the world. Although effective, safe and feasible in short-term treatment, long-term data are scarce and there is no recommendation for required treatment length. The aims of the study were to determine the perceived need of long-term XR-NTX treatment and to examine long-term treatment outcomes.
DESIGN
METHODS
In this prospective cohort study, following a parent 1-year study of XR-NTX, participants received treatment with XR-NTX at their own discretion for a maximum of 104 weeks.
SETTING
METHODS
Five urban, outpatient addiction clinics in Norway.
PARTICIPANTS
METHODS
Opioid-dependent adults 18-60 years old (n=50) already participating in the parent study.
INTERVENTION
METHODS
XR-NTX administrated as intra-muscular injections (380 mg) every 4 weeks.
MEASUREMENTS
METHODS
Time in the study, use of opioids and other illicit substances, opioid craving, and treatment satisfaction reported every 4 weeks.
FINDINGS
RESULTS
Among 58 participants who completed the 1-year parent study, 50 chose to continue the treatment with XR-NTX. Median prolonged treatment time was 44.0 weeks (95% CI: 25.5-62.5), ranging from 8 to 104 weeks. Most participants (35, 70%) reported no relapse to opioid use during treatment while a subgroup (15, 30%) reported relapses to opioids during the study. Scores for mean treatment satisfaction and recommending treatment to others were very high (>9) and mean opioid craving score was very low (<1) on a scale ranging from 0 to 10.
CONCLUSIONS
CONCLUSIONS
Extended-release naltrexone (XR-NTX) was well tolerated in long-term treatment of opioid dependent individuals in Norway already in XR-NTX treatment. On average, the participants chose to continue treatment for almost 1 year beyond the initial 9 to 12 months of treatment. Participants reported high treatment satisfaction and 70% showed no relapse to opioids during the treatment period.
Identifiants
pubmed: 33338285
doi: 10.1111/add.15378
pmc: PMC8359292
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
This article is protected by copyright. All rights reserved.
Références
JAMA Psychiatry. 2017 Dec 1;74(12):1197-1205
pubmed: 29049469
J Psychopharmacol. 2011 Jun;25(6):774-82
pubmed: 20360157
Drug Alcohol Depend. 2019 Dec 1;205:107649
pubmed: 31704382
Nat Rev Dis Primers. 2020 Jan 9;6(1):3
pubmed: 31919349
JAMA. 2005 Apr 6;293(13):1617-25
pubmed: 15811981
Curr Psychiatry Rep. 2014 Oct;16(10):489
pubmed: 25182514
Arch Gen Psychiatry. 1973 Jun;28(6):784-91
pubmed: 4707988
Addiction. 2013 Sep;108(9):1628-37
pubmed: 23701526
J Subst Abuse Treat. 2016 Mar;62:68-73
pubmed: 26654934
Addiction. 2011 Jul;106(7):1309-18
pubmed: 21320227
Drug Alcohol Depend. 2012 Jan 1;120(1-3):48-54
pubmed: 21782353
Psychopharmacology (Berl). 2006 Nov;189(1):37-46
pubmed: 16972105
Drug Alcohol Depend. 2017 Oct 1;179:213-219
pubmed: 28806638
Eur Addict Res. 2019;25(6):303-309
pubmed: 31340204
J Subst Abuse Treat. 2016 Nov;70:50-57
pubmed: 27692188
J Subst Abuse Treat. 2007 Oct;33(3):243-56
pubmed: 17889296
J Addict Dis. 2016;35(1):22-35
pubmed: 26467975
Harv Rev Psychiatry. 2015 Mar-Apr;23(2):63-75
pubmed: 25747920
Int J Drug Policy. 2017 Jan;39:109-113
pubmed: 27788405
Addiction. 2020 Dec 18;:
pubmed: 33338285
JAMA Psychiatry. 2019 Feb 1;76(2):127-134
pubmed: 30566177
Am J Addict. 2019 Feb;28(2):77-85
pubmed: 30701613
Cochrane Database Syst Rev. 2008 Apr 16;(2):CD006140
pubmed: 18425938
Lancet. 2018 Jan 27;391(10118):309-318
pubmed: 29150198
J Stud Alcohol Drugs. 2015 Jan;76(1):143-51
pubmed: 25486403
N Engl J Med. 2016 Mar 31;374(13):1232-42
pubmed: 27028913
Drug Alcohol Depend. 2013 Jan 1;127(1-3):163-9
pubmed: 22809895
Cochrane Database Syst Rev. 2009 Jul 08;(3):CD002209
pubmed: 19588333
N Engl J Med. 2014 May 29;370(22):2063-6
pubmed: 24758595
BMC Pharmacol Toxicol. 2016 Apr 28;17(1):18
pubmed: 27121539
Addiction. 2017 May;112(5):830-837
pubmed: 27936293
Expert Opin Pharmacother. 2016 Dec;17(17):2307-2318
pubmed: 27734745
Harv Rev Psychiatry. 2015 Mar-Apr;23(2):76-89
pubmed: 25747921
J Addict Med. 2020 Jul/Aug;14(4):331-336
pubmed: 31972765
J Subst Abuse Treat. 2016 Jul;66:48-53
pubmed: 27211996
J Addict Med. 2017 May/Jun;11(3):224-230
pubmed: 28358754
Drug Alcohol Depend. 2017 Jul 1;176:139-147
pubmed: 28535456
J Addict Med. 2015 Sep-Oct;9(5):358-67
pubmed: 26406300
Lancet. 2011 Apr 30;377(9776):1506-13
pubmed: 21529928
Subst Use Misuse. 2016 Dec 5;51(14):1905-11
pubmed: 27613150
Drug Alcohol Depend. 2009 Nov 1;105(1-2):9-15
pubmed: 19608355
Cochrane Database Syst Rev. 2014 Feb 06;(2):CD002207
pubmed: 24500948
Addiction. 2018 Oct;113(10):1840-1849
pubmed: 29806872
Am J Addict. 2017 Jun;26(4):319-325
pubmed: 28328148
Subst Abus. 2016;37(1):54-62
pubmed: 26158698
Arch Gen Psychiatry. 2006 Feb;63(2):210-8
pubmed: 16461865
Drug Alcohol Depend. 2018 Jul 1;188:200-208
pubmed: 29778774
Addiction. 2015 Jun;110(6):891-8
pubmed: 25490943